DE1467966A1 - Verfahren zur Herstellung eines pharmazeutischen Mittels mit Freigabeverzoegerung fuer die Asthma-Therapie - Google Patents

Verfahren zur Herstellung eines pharmazeutischen Mittels mit Freigabeverzoegerung fuer die Asthma-Therapie

Info

Publication number
DE1467966A1
DE1467966A1 DE19631467966 DE1467966A DE1467966A1 DE 1467966 A1 DE1467966 A1 DE 1467966A1 DE 19631467966 DE19631467966 DE 19631467966 DE 1467966 A DE1467966 A DE 1467966A DE 1467966 A1 DE1467966 A1 DE 1467966A1
Authority
DE
Germany
Prior art keywords
delay
beads
dose
layer
theophylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19631467966
Other languages
German (de)
English (en)
Inventor
Munch James C
Jack Kantor
Mark Shepard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Pharmaceuticals Inc
Original Assignee
Key Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Pharmaceuticals Inc filed Critical Key Pharmaceuticals Inc
Publication of DE1467966A1 publication Critical patent/DE1467966A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE19631467966 1961-01-31 1963-08-24 Verfahren zur Herstellung eines pharmazeutischen Mittels mit Freigabeverzoegerung fuer die Asthma-Therapie Pending DE1467966A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85978A US3109775A (en) 1961-01-31 1961-01-31 Theophylline-noscapine sustained release composition for treatment of asthma
DEK0050632 1963-08-24

Publications (1)

Publication Number Publication Date
DE1467966A1 true DE1467966A1 (de) 1969-02-20

Family

ID=25983781

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19631467966 Pending DE1467966A1 (de) 1961-01-31 1963-08-24 Verfahren zur Herstellung eines pharmazeutischen Mittels mit Freigabeverzoegerung fuer die Asthma-Therapie

Country Status (5)

Country Link
US (1) US3109775A (pt)
BE (1) BE636568A (pt)
DE (1) DE1467966A1 (pt)
GB (1) GB935601A (pt)
NL (1) NL297088A (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
CA1165241A (en) * 1980-05-06 1984-04-10 Bristol-Myers Squibb Company Sustained release theophylline tablet having reduced bulk
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
JPS58501128A (ja) * 1981-07-15 1983-07-14 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 徐放性テオフイリン
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4876094A (en) * 1984-01-13 1989-10-24 Battelle Development Corporation Controlled release liquid dosage formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
CA1309022C (en) * 1986-04-07 1992-10-20 Richard James Harwood Method for the preparation of a sustained release pharmaceutical composition and the composition prepared thereby
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
FI77573C (fi) * 1987-05-08 1989-04-10 Orion Yhtymae Oy Ny konsistens.
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
GB0227948D0 (en) * 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2752285A (en) * 1950-10-09 1956-06-26 Weissenburger Helmut Process for the production of at least approximately neutral solutions of substituted xanthines
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2881085A (en) * 1953-11-09 1959-04-07 Abbott Lab Thin film coating for tablets and the like
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
NL108838C (pt) * 1956-03-27
US2954323A (en) * 1958-10-06 1960-09-27 Abbott Lab Thin film coating for tablets and the like
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
NL122039C (pt) * 1960-10-20

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation

Also Published As

Publication number Publication date
US3109775A (en) 1963-11-05
GB935601A (en) 1963-08-28
NL297088A (pt)
BE636568A (pt)

Similar Documents

Publication Publication Date Title
DE1467966A1 (de) Verfahren zur Herstellung eines pharmazeutischen Mittels mit Freigabeverzoegerung fuer die Asthma-Therapie
DE69730991T2 (de) Alginsaure enthaltende enterischer ueberzug fuer eine orale zubereitung
EP0032562B1 (de) Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung
DE3915150C2 (de) Lang-wirkendes Diclofenac-Natrium-Präparat
DE2618129A1 (de) Feste, subkutan implantierbare pille, enthaltend eine biologisch wirksame menge an 2 alpha-methylandrostan-17beta- 0l-3-on-17-propionat, verfahren zu deren herstellung und anwendung
DE1467961A1 (de) Medikamententraegerstoffe mit Freigabeverzoegerung und Verfahren zu ihrer Herstellung
DE1467976A1 (de) Traegermassen fuer Pharmazeutika und Verfahren zu ihrer Herstellung
DE2813480A1 (de) Arzneimittel-depotpraeparat vom mehrfacheinheitsdosen-typ
DE2224534A1 (de) Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe
CH630259A5 (de) Verfahren zur herstellung von dragees.
EP0386440A1 (de) Arzneimittel mit kontrollierter Wirkstoffabgabe
DE1292783B (de) Verfahren zum Herstellen einer Tablette mit Depotwirkung
DE2950463A1 (de) Gallensaeuren enthaltende pharmazeutische zubereitung mit verlaengerter wirkungsdauer
EP0469328B1 (de) Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen
EP0250648A2 (de) Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen
DE60006362T2 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
EP2974733B1 (de) Kombination von Baldrianwurzelextrakt und Lavendelöl zur Verwendung zur Behandlung von Schlafstörungen
DE69919003T2 (de) Acetaminophen-formulierung mit verlängerter freisetzung
DE3638124C2 (de) Neue pharmazeutische Verwendung von Ebselen
DE2343218A1 (de) Zubereitungsformen von n-(2-furfuryl)4-chlor-5-sulfamoylanthranilsaeure und verfahren zu ihrer herstellung
DE1963496A1 (de) Pharmazeutisches Praeparat zur Behandlung von Magen-Darm-Erkrankungen
WO2011141108A2 (de) Neue darreichungsformen für cineol
DE2654743C2 (de) Verwendung eines Gemisches als Therapeutikum zur externen Behandlung von Schuppenflechte (Psoriasis), Flechten und Ekzemen
DE3315607A1 (de) Verwendung von albendazol in oraler verabreichungsform bei der bekaempfung von echinokokkose des menschen und arzneimittel
EP2804595B1 (de) Systemische darreichungsformen mit kontrollierter freisetzung und verbesserter stabilität